Compare Becton Dickinson and Co (BDX) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Petróleo Brasileiro SA — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Petróleo Brasileiro SA trades at $17.97 (market cap $108.05B). The key difference: Petróleo Brasileiro SA is far larger — about 2.6× Becton Dickinson and Co's market cap, and Petróleo Brasileiro SA pays the higher dividend (9.84%). Which is the better fit depends on your goals.
| BDX | PBR | |
|---|---|---|
Market Cap | $41.51B | $108.05B |
Sector | Health | Technology |
52-Week High | $185.39 | $22.03 |
52-Week Low | $135.49 | $11.54 |
Enterprise Value | $57.97B | $170.59B |
Dividend Yield | 2.79% | 9.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
PBR trades at $17.88, up 3.23% today, with bullish technical signals from moving averages and ADX indicators. The stock shows strong fundamentals with a P/E of 5.71, net income margin of 21.47%, and consistent dividend payments. Recent developments include strategic acquisitions in Africa and renewable energy investments, supporting growth prospects amid positive analyst sentiment.
Outlook remains favorable with a consensus price target of $23.90, representing 33.6% upside potential. Key risks include oil price volatility and execution of new projects. The combination of low valuation, robust cash flow, and strategic expansion provides a compelling case for long-term investors, though market fluctuations warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
